Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses

Bone Marrow Transplantation

Volumn 32, Issue 5, 2003, Pages 495-504

  Ji, Y H ^a   Weiss, L ^a   Zeira, M ^a   Abdul Hai, A ^a   Reich, S ^a   Schuger, L ^a,b   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cell leukemia; Cytokines; Immunization; Mice; Transplantation

Indexed keywords

ALLOANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CELL STRAIN; CONTROLLED STUDY; DATA ANALYSIS; DONOR; DOWN REGULATION; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HOST CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE TRANSFUSION; MAJOR HISTOCOMPATIBILITY COMPLEX; MINOR HISTOCOMPATIBILITY COMPLEX; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SPLEEN CELL; TH1 CELL; TH2 CELL; TUMOR CELL; UPREGULATION;

ANIMALS; CYTOKINES; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, B-CELL; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED STRAINS; SPLEEN; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0141702029     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704150     Document Type: Article

References (44)

1. Weiden PL, Fluornoy N, Sanders JE et al. Anti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 1981; 13: 248-251.
2. Horowitz MM, Gale RP, Sondel PM et al. Graft-vs-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
3. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes. N Engl J Med 2000; 343: 802-803.
4. Slavin S, Weiss L, Morecki S et al. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 1981; 11: 155-158.
5. Weiss L, Lubin I, Factorowich I et al. Effective graft vs leukemia effects independent of graft vs host disease after T-cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and rIL-2. J Immunol 1994; 153: 2562-2567.
6. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-vs-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 1991; 77: 2515-2523.
7. Slavin S, Strober S. Spontaneous murine B-cell leukaemia. Nature 1978; 272: 624-626.
8. Slavin S, Weiss L, Morecki S et al. Ultrastructural, cell membrane and cytogenetic characteristics of B-cell leukemia, a murine model of chronic lymphocytic leukemia. Cancer Res 1981; 41: 4162-4166.
9. Sander B, Hoiden I, Anderrson U et al. Similar frequencies and kinetics and cytokine producing cells in murine peripheral blood and spleen. Cytokine detection by immunoassay and intracellular immunostaining. J Immunol Methods 1993; 166: 201-214.
10. Abrams JS. Immunoenzymetric assay of mouse and human cytokines using NIP-labeled anti-cytokine antibodies. In: Caligan J, Knisbeck A, Margulis D, Shevach E, Strober W (eds). Current Protocols in Immunology. John Wiley and Sons: New York, 1995.
11. Cohen P, Vourka-Karussis U, Weiss L, Slavin S. Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. J Immunol 1993; 151: 4803-4810.
12. Pugatsch T, Weiss L, Slavin S. Minimal residual disease in murine B cell leukemia (BCL1) Detected by PCR. Leuk Res 1993; 17: 999-1002.
13. Wilcoxon F. Individual comparisons by rank methods. Biometrics 1945; 1: 80-83.
14. Weiss L, Morecki S, Vitetta ES et al. Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation. J Immunol 1983; 130: 2452-2455.
15. Slavin S, Ackerstein A, Weiss L. Adoptive immunotherapy in conjunction with bone marrow transplantation - amplification of natural host defense mechanisms against cancer by recombinant IL-2. Nat Immun Cell Growth Regul 1988; 7: 180-184.
16. 1). Int J Cancer 1996; 65: 204-208.
17. Yefenof E, Picker LJ, Scheuermann RH et al. Cancer dormancy; isolation and characterization of dormant 1 cells. Proc Natl Acad Sci USA 1993; 90: 1829-1833.
18. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
19. Van Lochem E, De Grast B, Goulmy E. In vitro separation of host specific graft-versus-host disease and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992; 10: 181-183.
20. Zeis M, Uharek L, Glass B et al. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukemia effect in mice. Br J Haematol 1997; 96: 757-761.
21. Slavin S, Ackerstein A, Kedar E, Weiss L. IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL2. Bone Marrow Transplant 1990; 6 (Suppl 1): 86-90.
22. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
23. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte infusions in marrow grafted patients. Blood 1995; 86: 41-50.
24. Zeis M, Uharek L, Glass B et al. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation. Exp Hematol 1998; 26: 1068-1073.
25. Morecki A, Puyesky Y et al. Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell surface idiotype and the costimulatory B7 molecule. Cancer Immunol Immunother 1995; 41: 236-242.
26. Morecki S, Yacovlev E, Gelfand Y et al. Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother 2001; 24: 114-121.
27. Blazar BR, Roopenian DC, Taylor PA et al. Lack of GVHD across classical, single minor histocompatibility (miH) locus barriers in mice. Transplantation 1996; 61: 619-624.
28. Rocha M, Umansky V, Lee KH et al. Differences between graft-versus-leukemia and graft-versus-host reactivity. Interaction of donor immune T cells with tumor and/or host cells. Blood 1997; 89: 2189-2202.
29. Blazar BR, Taylor PA, Panoskaltsis N et al. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo all responses in marine recipients of MHC disparate T cells. J Immunol 1999; 162: 6368-6377.
30. De La Selle V, Riche N, Dorothe G et al. CD8+ cytotoxic T cell repertoire implicated in graft-vs-leukemia effect in a murine bone marrow transplantation model. Bone Marrow Transplant 1999; 23: 951-958.
31. Taylor PA, Panoskatsis N, Mortari A et al. Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibody. J Immunol 2000; 164: 612-622.
32. Weiss L, Weigensberg M, Morecki S. Characterization of effector cells of graft-vs-leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1). Cancer Immunol Immunother 1990; 31: 236-242.
33. Okubo T, Hagiwara E, Ohno S et al. Administration of an IL-12-encoding DNA plasmid prevents the development of chronic graft-versus-host disease (GVHD). J Immunol 1999; 162: 4013-4017.
34. Blazar BR, Taylor PA, Panoskaltsis N et al. Rapamycin inhibits the generation of graft-versus-host disease and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol 1998; 160: 5355-5365.
35. Sefrioui H, Billiau AD, Overbergh L et al. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells. Transplantation 1999; 68: 1560-1567.
36. Krenger W, Snyder KM, Byon JC et al. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995; 155: 585-593.
37. Salgame P, Abrams JS, Clayberger C et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991; 254: 279-282.
38. Seder RA, Boulay JL, Finkelman F et al. CD8+ T cells can be primed in vitro to produce IL-4. J Immunol 1992; 148: 1652-1656.
39. Fowler DH, Kurasawa K, Husebekk A et al. Cells of the Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 1994; 152: 1004-1013.
40. Slavin S, Nagler A, Naparstek E et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.
41. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
42. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB × NZW) F1 hybrids with spontaneous lymphosarcoma. J Immunol 1984; 132: 997-1000.
43. Morecki S, Moshel Y, Gelfand Y et al. Induction of graft vs tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer 1997; 71: 59-63.
44. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.